MicroRNAs As Novel Biomarkers For Detection of Triple-Negative Breast Cancer

MicroRNA 作为检测三阴性乳腺癌的新型生物标志物

• 批准号: 8521186
• 负责人: Dezheng Huo
• 金额: $ 16.15万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-02 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8521186
• 关键词: Age; Bioinformatics; Biological; Biological Markers; Blood; Blood Circulation; Breast; Breast Cancer Detection; Breast Cancer Early Detection; Breast Cancer Prevention; Cancer Control; Cancer Patient; Cancerous; Chicago; Clinical; Data; Databases; Detection; Development; Diagnostic; Frequencies; Functional RNA; Gene Expression; Gene Targeting; Goals; Housing; Malignant Neoplasms; Mammary Gland Parenchyma; Mammary Neoplasms; Mammography; Measures; Methods; MicroRNAs; Molecular Profiling; Normal tissue morphology; Outcome; Pathologic; Patients; Plasma; Play; Population Heterogeneity; Primary Neoplasm; Proteins; RNA; Regulator Genes; Research; Rest; Reverse Transcriptase Polymerase Chain Reaction; Risk; Role; Sampling; Serum; Small RNA; Specimen; Testing; Tissue Microarray; Tissues; Translating; Tumor Subtype; Tumor Tissue; United States; Universities; Validation; Woman; base; carcinogenesis; case control; clinically relevant; cost effective; density; epidemiologic data; genome-wide; innovation; mRNA Expression; malignant breast neoplasm; mortality; novel; programs; repository; screening; tool; triple-negative invasive breast carcinoma

DESCRIPTION (provided by applicant): Breast cancer is the most common cancer among women both in the United States and globally. Current screening programs are not completely successful in reducing breast cancer mortality. There is a great need to continue searching for novel non-invasive biomarkers for breast cancer detection and screening. A paradigm shift is to focus on biomarkers that identify aggressive form of breast cancer, rather than lumping all breast cancer together. MicroRNAs represent a class of emerging and attractive cancer biomarkers because they maintain in a protected state in serum and plasma, have tissue-specific expression profiles, and can be uniformly amplified and quantified. In this application, we propose to systematically identify microRNAs in serum that are differentially expressed between 30 triple-negative breast cancers, 30 other breast cancers, and 40 matched controls, followed by a replication study in an independent sample of 60 cases and 40 controls. To prioritize and select putative microRNAs, we will also examine the concordance of microRNA levels in the serum and breast tissues of breast cancer patients, and explore their biologic relevance using bioinformatics approach and experimental validation. All biospecimens have been collected in previous breast cancer studies. This study has several innovative aspects including its systematic unbiased approach, focusing on aggressive tumor subtypes, and integrated approach for assessing biological relevant miRNAs using ethnically diverse population. This study is directly translational and will open the door to new strategy of breast cancer prevention and control.

描述（由申请人提供）：乳腺癌是美国和全球女性中最常见的癌症。当前的筛查计划在降低乳腺癌死亡率方面并不完全成功。非常需要继续寻找新型的非侵入性生物标志物进行乳腺癌检测和筛查。范式的转变是关注鉴定侵略性乳腺癌形式的生物标志物，而不是将所有乳腺癌结合在一起。 microRNA代表一类新兴和有吸引力的癌症生物标志物，因为它们保持在血清和血浆中的保护状态，具有组织特异性的表达谱，并且可以均匀地放大和定量。在此应用中，我们建议系统地识别血清中的microRNA，这些microRNA在30种三阴性乳腺癌，其他30种其他乳腺癌和40个匹配的对照中差异表达，然后在60例和40例对照的独立样本中进行复制研究。为了确定和选择推定的microRNA，我们还将检查乳腺癌患者血清和乳房组织中microRNA水平的一致性，并使用生物信息学方法和实验验证探索其生物学相关性。所有生物测量均已在先前的乳腺癌研究中收集。这项研究具有几个创新的方面，包括其系统的无偏见方法，专注于侵袭性肿瘤亚型，以及使用种族多样性种群评估生物学相关miRNA的综合方法。这项研究直接转化，将为预防乳腺癌预防和控制的新策略打开大门。